SC
DFTX

Scotia Capital’s Definium Therapeutics DFTX Stock Holding History

Scotia Capital’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$766K Sell
40,548
-9,129
-18% -$155K ﹤0.01% 609
2025
Q4 		$664K Sell
49,677
-4,254
-8% -$52.6K ﹤0.01% 621
2025
Q3 		$636K Hold
53,931
– – ﹤0.01% 633
2025
Q2 		$350K Sell
53,931
-44
-0.1% -$289 ﹤0.01% 688
2025
Q1 		$315K Buy
53,975
+20
+0% +$143 ﹤0.01% 695
2024
Q4 		$376K Buy
53,955
+4
+0% +$28 ﹤0.01% 666
2024
Q3 		$307K Hold
53,951
– – ﹤0.01% 690
2024
Q2 		$390K Hold
53,951
– – ﹤0.01% 643
2024
Q1 		$506K Sell
53,951
-67,805
-56% -$387K ﹤0.01% 595
2023
Q4 		$441K Buy
+121,756
New +$367K ﹤0.01% 600
2022
Q3 		– Sell
-6,103
Closed -$58K – 819
2022
Q2 		$58K Buy
6,103
+517
+9% +$6.54K ﹤0.01% 776
2022
Q1 		$93K Sell
5,586
-255
-4% -$4.42K ﹤0.01% 840
2021
Q4 		$120K Buy
5,841
+298
+5% +$9.51K ﹤0.01% 830
2021
Q3 		$194K Hold
5,543
– – ﹤0.01% 801
2021
Q2 		$288K Buy
+5,543
New +$291K ﹤0.01% 724

Other funds holding DFTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Scotia Capital's DFTX Position: Q1 2026 in Review

Scotia Capital reduced its Definium Therapeutics (DFTX) stake by 18% in Q1 2026, selling an estimated $155K and leaving 40,548 shares worth $766K. The position accounts for ﹤0.01% of the portfolio, ranked #609.

Scotia Capital first reported a position in DFTX in Q2 2021 and has held it in 15 quarters since. 247 funds tracked by Wall St. Rank hold DFTX as of Q1 2026.

  • Scotia Capital held 40,548 shares of Definium Therapeutics worth $766K as of Q1 2026.
  • Scotia Capital sold 9,129 Definium Therapeutics shares in Q1 2026, an estimated $155K.
  • Definium Therapeutics made up ﹤0.01% of Scotia Capital's portfolio in Q1 2026, its #609 holding.
  • Scotia Capital first reported a position in Definium Therapeutics in Q2 2021 and has held it in 15 quarters since.
  • 247 funds tracked by Wall St. Rank held Definium Therapeutics as of Q1 2026.

Based on Scotia Capital's 13F filing for Q1 2026, filed 13 May 2026.